These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37048621)

  • 1. A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients.
    Soliman T; Gyoeri G; Salat A; Mejzlík V; Berlakovich G
    J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
    Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
    Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
    Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
    Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
    Bilbao I; Gómez Bravo MÁ; Otero A; Lladó L; Montero JL; González Dieguez L; Graus J; Pons Miñano JA
    Clin Transplant; 2023 Dec; 37(12):e15105. PubMed ID: 37615653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year outcomes of de novo tacrolimus extended-release tablets (LCPT) compared to twice-daily tacrolimus in adult heart transplantation.
    Alam A; van Zyl JS; Patel R; Jamil AK; Felius J; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA; Sam T
    Transpl Immunol; 2024 Apr; 83():102009. PubMed ID: 38325525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
    Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
    Transpl Int; 2022; 35():10225. PubMed ID: 36017158
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience.
    Huang X; Hapgood K; Allan K; Pruette C; Goswami E
    Pediatr Transplant; 2024 Feb; 28(1):e14611. PubMed ID: 37735900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.
    van Zyl JS; Sam T; Clark DM; Felius J; Doss AK; Kerlee KR; Cheung ZO; Martits-Chalangari K; Jamil AK; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA
    Clin Transplant; 2021 Dec; 35(12):e14487. PubMed ID: 34529289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
    Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
    Transpl Int; 2024; 37():11571. PubMed ID: 38694490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study.
    Romine MM; Leeser DB; Kennamer K; Nguyen C; Jones H; McLawhorn K; Kendrick S; Irish W
    Clin Transplant; 2024 Mar; 38(3):e15268. PubMed ID: 38450751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
    Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
    Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
    Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
    Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Administration of Once-Daily MeltDose
    Willuweit K; Frey A; Hörster A; Saner F; Herzer K
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.
    Bunnapradist S; Ciechanowski K; West-Thielke P; Mulgaonkar S; Rostaing L; Vasudev B; Budde K;
    Am J Transplant; 2013 Mar; 13(3):760-9. PubMed ID: 23279614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
    Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
    J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.